Nanobody Discovery Service for CAR-T and Cell Therapy Development

Successful CAR-oriented nanobody discovery requires more than simple target binding. Candidate binders must recognize native cell-surface antigens, exhibit suitable affinity profiles, maintain functional activity in CAR formats, and minimize off-target interactions.

To address these challenges, our discovery workflows integrate membrane protein-focused immunization strategies, cell-based screening, and quantitative display technologies to enable efficient identification of CAR-compatible nanobody candidates.

Why Nanobodies for CAR Development?

Compact and Modular Architecture

The small VHH format enables efficient CAR construction and flexible multi-specific engineering.

Reduced Aggregation Risk

Compared with scFvs, nanobodies generally show lower aggregation tendencies, helping reduce tonic signaling risk.

Excellent Membrane Protein Recognition

Nanobodies are highly suitable for recognizing native membrane proteins and conformational epitopes.

Compatibility with Advanced CAR Designs

Supports dual-target, tandem, and logic-gated CAR architectures.

Our CAR-Oriented Nanobody Discovery Strategy

Our workflows are specifically optimized for CAR and cell therapy applications, with a focus on membrane protein targeting, epitope selection, and downstream CAR compatibility.

Key considerations include:

Membrane Protein-Focused Discovery

Cell-surface antigen recognition

Epitope-Focused Screening

Minimization of off-target binding

Discovery Workflow Options

Immunization-Based Workflow

Camelid immunization → PBMC isolation → Library construction → Binder screening → Validation(Optional)

Recommended for therapeutic CAR development programs requiring high-diversity and suitable-affinity binders.

Premade Library Workflow

Premade library selection → Binder screening → Validation(Optional)

Recommended for rapid target validation and early-stage exploratory programs.

Deliverables

Clients will receive:

CAR-suitable nanobody sequences

Candidate binder analysis report

Expression-ready constructs (optional)

Binding validation data (optional)

Comprehensive project report

Optional downstream services:

Nanobody humanization

Affinity maturation

Typical Project Timeline

Option 1 — Immunization-Based Discovery

Stage	Deliverables	Timeline
Immunization	Serum titer report	8 weeks
Library construction	Immune phage or yeast display library	3–4 weeks
Library screening	Enriched CAR-oriented binders	4-6 weeks
Optional candidate production	Purified VHH and expression-ready constructs	2–3 weeks
Optional validation	Binding and functional assay data	2–4 weeks

Typical total timeline:

Approximately 15-18 weeks depending on project complexity and screening strategy.

Option 2 — Premade Library Screening

Stage	Deliverables	Timeline
Library screening	Enriched CAR-oriented binder sequences	4-6 weeks
Optional candidate production	Purified VHH or expression-ready constructs	2–3 weeks
Optional validation	Binding and functional assay data	2–4 weeks

Typical total timeline:

Approximately 4–13 weeks depending on validation requirements.

Advantages of Our CAR Nanobody Discovery Platform

Discovery strategies optimized for CAR applications

Strong expertise in membrane protein targeting

Integrated phage and yeast display platforms

Cell-based screening capability

FAQs

Can your platform support membrane protein and cell-surface antigen discovery?

Yes. Our workflows are specifically optimized for native membrane protein recognition using:

● Cell-based immunization and screening strategies

● Cell-surface binding validation

● Functional display technologies

● Epitope-focused selection approaches

This helps enrich binders that recognize physiologically relevant antigen conformations.

Do you provide both immunization-based and synthetic/premade library workflows?

Yes. We offer:

● Immunization-based discovery for therapeutic programs requiring high diversity and affinity maturation potential

● Premade library screening for rapid exploratory or early validation projects

We can also help recommend the most suitable strategy based on timeline, target complexity, and development stage.

What affinity range is typically preferred for CAR applications?

The optimal affinity depends on the target biology and therapeutic strategy. Extremely high affinity is not always ideal for CAR-T applications. In many cases, moderate affinity binders may improve tumor selectivity and reduce off-tumor activity. Our screening workflows can be adjusted to support affinity tuning objectives.

Which workflow is better for therapeutic CAR development?

For most therapeutic CAR-T programs, immunization-based workflows are generally preferred because they often generate higher-diversity repertoires, better epitope coverage, more naturally matured binders, and improved developability profiles. Premade libraries are often suitable for rapid feasibility studies or early-stage target validation.

Can you screen for binders recognizing native cell-surface antigens instead of recombinant proteins only?

Yes. This is a major focus of our CAR-oriented discovery strategy. This helps reduce the risk of identifying binders that fail in CAR cellular contexts.

For CAR-oriented VHH discovery, phage display or yeast display—which is more suitable, and what should be considered?

Selection depends on antigen format and required native conformation relevance for CAR function.

Phage display is generally preferred for CAR-target discovery against cell-surface or membrane proteins, especially when:

● Native membrane conformation is critical

● Recombinant proteins may not reflect physiological structure

● Cell-based or native antigen screening is required

Many membrane targets differ between recombinant and cell-surface forms, so phage-based cell screening better preserves CAR-relevant epitope context.

Yeast display is more suitable for:

● Purified recombinant protein screening

● Well-folded, structurally stable antigens

● Affinity maturation or quantitative binding optimization

It is generally less ideal for direct cell-based selection due to larger cell size and higher background in cell-sorting assays, which can reduce specificity resolution.

Practical selection guideline

● Phage display best for native membrane/cell-based, CAR-relevant epitope discovery

● Yeast display best for recombinant protein systems and downstream affinity optimization

In CAR nanobody discovery, platform choice should prioritize how closely the screening antigen mimics the final cell-surface CAR target context.

How do you minimize off-target binding risk?

We incorporate several risk-reduction strategies, including:

● Counter-screening against negative cell lines

● Specificity-focused selection workflows

● Epitope-focused screening

● Cell-based validation assays

Optional downstream characterization can further evaluate specificity profiles.

What validation assays can be included?

Optional validation services may include:

● Cell-surface binding assays

● Cross-reactivity assessment

● Internalization analysis

● Basic functional characterization

Validation scope can be customized based on project requirements.